The nation of Zimbabwe has turned down a substantial American healthcare agreement valued at $367m (£272m) spanning five years because of the United States' demand for confidential information.
This rejection became public following a government memo dated December was leaked, indicating that Head of State Emmerson Mnangagwa felt the agreement was "unbalanced".
An official spokesman has since clarified that the US was seeking genetic material for research and profit while was not willing to share the resulting advantages from future treatments.
"We will now turn to the challenging and unfortunate task of ending our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had provided over $1.9bn for health programmes to Zimbabwe during the past two decades.
A medical body in Zimbabwe has called for further dialogue to find a agreement acceptable to both sides so the country's critical HIV programme can be sustained.
Wider Implications
Zimbabwe's decision follows a comparable situation in neighbouring Kenya, where a high court blocked a related deal with the US after legal challenges were filed about the safety of citizens' health data.
After resuming office recently, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
The agency had managed assistance for the US government, but Trump argued its expenditure was "wasteful" and his administration was pursuing government-to-government agreements to boost openness and responsibility.
As per reports, 16 nations in Africa have so far signed similar agreements, constituting over $18.3bn in committed funds.
Details of the Declined Agreement
The money for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this partnership would have delivered immense benefits for Zimbabwean communities, especially the 1.2 million presently on antiretroviral therapy through US-supported initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"The proposal required Zimbabwe to share its biological resources and data indefinitely, with no corresponding guarantee of benefiting from any medical innovations – like new medicines or tests – that could be developed from that shared data," he stated.
"In essence, our country would provide the raw materials for medical research without any assurance that the resulting innovations would be available to our people if a future pandemic arise."
National Interest and International Frameworks
He also said that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one deals were undermining systems previously established via the global health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework designed to manage future pandemics.
"This system is intended to guarantee that when a nation provides its samples, the benefits – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the capability to create them."
Zimbabwe's reservations over the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We welcome ongoing discussions with our US partners on how future collaboration could be designed in a way that respects the independence and interests of each country."
Health Experts Response
A leading public health body stated it acknowledged the official position, but recommended that talks must proceed considering a large portion of the nation's Aids initiatives were funded by external financing.
"Where specific concerns arise, including those involving data governance or implementation frameworks, these can frequently be resolved through detailed discussion and negotiated safeguards," it said.
The halted deal highlights the complex challenges between accepting much-needed international aid and safeguarding national sovereignty in an ever more data-driven world.